Cysteine conjugate of methazolamide is metabolized by beta-lyase

J Pharm Sci. 2001 Feb;90(2):224-33. doi: 10.1002/1520-6017(200102)90:2<224::aid-jps13>3.0.co;2-0.

Abstract

Bovine kidney and liver homogenates degraded a cysteine conjugate of methazolamide, S-(5-acetylimino-4-methyl-Delta2-1,3,4-thiadiazolin-2-yl)cysteine. We isolated the degradation product following incubation with kidney homogenate by high-performance liquid chromatography on reversed-phase columns. The chemical structure was confirmed by proton and carbon-13 nuclear magnetic resonance spectroscopy (1H NMR and 13C NMR, respectively), and elemental analysis by high-resolution mass spectrometry to be N-(3-methyl-5-mercapto-Delta4-1,3,4-thiadiazol-2-yl)acetamide, a thiol compound. The reaction is thought to be catalyzed by a pyridoxal-dependent enzyme(s) as indicated by an inhibition study using aminooxyacetic acid. Possible involvement of the thiol compound in the development of an adverse effect is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carbon-Sulfur Lyases / metabolism*
  • Carbonic Anhydrase Inhibitors / chemistry
  • Carbonic Anhydrase Inhibitors / metabolism*
  • Cattle
  • Cysteine / metabolism*
  • Kidney / metabolism
  • Liver / metabolism
  • Methazolamide / chemistry
  • Methazolamide / metabolism*
  • Spectrum Analysis

Substances

  • Carbonic Anhydrase Inhibitors
  • Carbon-Sulfur Lyases
  • cysteine-S-conjugate beta-lyase
  • Cysteine
  • Methazolamide